Bionomics Results Presentation Deck

Statistical Significance is Achieved when Task Phases are Combined Combining SUDS from all Task Phases is the Optimal Endpoint for Late-Stage Development in SAD AUC of Change in SUDS for Anticipation and Speaking Phases Results of Combined Speaking Task Phases ● 30 25 19 20 15 10 5 -5 -10 MMRM R- P5* AUC A0-P5 • Statistical significance was observed using the selected primary outcome (SUDS) in task stage analysis in the combined dose arm group (increased power) -15 BL R A0 A1 A2 PO P1 P2 P3 P4 P5 R1 R2 R3 Anticipation+Performance *Post-hoc analyses **BNC210 225 mg matched estimated 300 mg Cmax concentrations seen in GAD trial Analysis was based on the observation that BNC210 demonstrated pharmacological activity throughout the public speaking task AUC A+P^^ Resting/Anticipation+Performance H Resting/AUC A+P^ -200 BNC210 225 mg -150 -100 Better than Placebo BNC210 675 mg -50 ^ Mixed model for repeated measures (MMRM); ^^ ANCOVA 0 Diff from Placebo (95% Cl) P value -85.40 [-194.45 - 23.65] 0.124 -108.80 [-219.39 - 1.79] 0.054 -96.79 [-190.85 -2.73] 0.044 -60.20 [-123.40 - 2.90] 0.061 -55.50 [-118.30 - 7.40] 0.083 -57.80 [-112.20 - -3.40] 0.037 Worse than Placebo 225 mg BNC210 was confirmed as the dose for late-stage development* BNC210 Overall .** Bionomics

View entire presentation